Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLife Science Regulatory News (LABS)

  • This share is currently suspended. It was suspended at a price of 43.10
  • There is currently no data for LABS

Form 8.3 LIFE SCIENCE REIT PLC

6 Feb 2026 11:23

RNS Number : 0840S
Barclays PLC
06 February 2026
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

LIFE SCIENCE REIT PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

05 Feb 2026

(f)

In addition to the company in 1(c) above, is the discloser making

YES:

 

 

 

disclosures in respect of any other party to the offer?

BRITISH LAND CO PLC/THE

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

1p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

167,408

0.05%

443,790

0.13%

(2)

Cash-settled derivatives:

 

 

 

 

 

 

 

 

76,487

0.02%

155,217

0.04%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

243,895

0.07%

599,007

0.17%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

1p ordinary

Purchase

156,911

0.4323 GBP

1p ordinary

Purchase

71,266

0.4294 GBP

1p ordinary

Purchase

44,779

0.4289 GBP

1p ordinary

Purchase

27,837

0.4316 GBP

1p ordinary

Purchase

26,074

0.4300 GBP

1p ordinary

Purchase

19,691

0.4400 GBP

1p ordinary

Purchase

8,888

0.4339 GBP

1p ordinary

Purchase

1

0.4280 GBP

1p ordinary

Sale

209,345

0.4319 GBP

1p ordinary

Sale

62,208

0.4296 GBP

1p ordinary

Sale

52,429

0.4400 GBP

1p ordinary

Sale

9,058

0.4280 GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

1p ordinary

SWAP

Decreasing Long

1

0.4300 GBP

1p ordinary

SWAP

Decreasing Short

11,472

0.4400 GBP

1p ordinary

CFD

Decreasing Short

21,266

0.4400 GBP

1p ordinary

CFD

Increasing Short

44,779

0.4289 GBP

1p ordinary

CFD

Increasing Short

10,365

0.4348 GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercise

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i) the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

06 Feb 2026

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETAKABKDBKDABK
Date   Source Headline
29th Jan 202612:19 pmRNSForm 8.3 - British Land Co PLC, The
29th Jan 202612:13 pmRNSForm 8.3 - Life Science REIT PLC
29th Jan 202611:58 amRNSForm 8.5 (EPT/RI)- Life Science REIT plc
29th Jan 202611:49 amRNSForm 8.3 Life Science REIT Plc
29th Jan 202611:39 amRNSForm 8.5 (EPT/RI)
29th Jan 202610:09 amRNSForm 8.5 (EPT/RI)-Life Science REIT plc
29th Jan 202610:06 amRNSForm 8.3
29th Jan 202610:02 amRNSForm 8.5 (EPT/NON-RI)-Life Science REIT plc
28th Jan 20262:54 pmRNSForm 8.3 - Life Science REIT plc
28th Jan 20262:19 pmRNSForm 8.3 - Life Science REIT Plc
28th Jan 20261:55 pmRNSForm 8.3 - British Land Company plc, The
28th Jan 20261:52 pmRNSForm 8.3 - Life Science REIT plc
28th Jan 202611:47 amRNSForm 8.3 - Life Science REIT plc
28th Jan 202610:22 amRNSForm 8.3 - Life Science REIT plc
28th Jan 20267:50 amRNSDisclosure Table
28th Jan 20267:00 amRNSRecommended offer for Life Science REIT PLC
27th Jan 20262:39 pmRNSHolding(s) in Company
26th Jan 20262:38 pmRNSHolding(s) in Company
26th Jan 202610:48 amRNSHolding(s) in Company
23rd Jan 20264:49 pmRNSHolding(s) in Company
23rd Jan 20262:58 pmRNSHolding(s) in Company
22nd Jan 20264:16 pmRNSHolding(s) in Company
22nd Jan 20263:16 pmRNSHolding(s) in Company
21st Jan 20262:56 pmRNSHolding(s) in Company
16th Jan 202612:17 pmRNSHolding(s) in Company
15th Jan 20263:43 pmRNSHolding(s) in Company
14th Jan 20264:59 pmRNSHolding(s) in Company
9th Jan 20267:00 amRNSPortfolio Valuation and NTA Update
22nd Dec 20253:01 pmRNSHolding(s) in Company
22nd Dec 20253:01 pmRNSHolding(s) in Company
16th Dec 20255:19 pmRNSHolding(s) in Company
3rd Dec 20257:00 amRNSAppointment of Non-Executive Director
1st Dec 202510:17 amRNSHolding(s) in Company
26th Nov 20254:34 pmRNSHolding(s) in Company
24th Nov 20253:58 pmRNSResult of Meeting
20th Nov 202510:12 amRNSHolding(s) in Company
19th Nov 202510:07 amRNSHolding(s) in Company
13th Nov 20253:02 pmRNSHolding(s) in Company
6th Nov 20255:19 pmRNSHolding(s) in Company
5th Nov 20259:43 amRNSHolding(s) in Company
4th Nov 20257:00 amRNSPublication of Circular & Notice of GM
20th Oct 20255:03 pmRNSHolding(s) in Company
20th Oct 20253:53 pmRNSHolding(s) in Company
17th Oct 20253:58 pmRNSHolding(s) in Company
16th Oct 20253:36 pmRNSHolding(s) in Company
10th Oct 20253:13 pmRNSForm 8.3 - Life Science REIT plc
3rd Oct 20255:59 pmRNSHolding(s) in Company
23rd Sep 20253:17 pmRNSForm 8.3 - Life Science REIT plc
23rd Sep 20257:00 amRNSHalf Year Results
22nd Sep 20253:22 pmRNSForm 8.3 - Life Science REIT plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.